Cantor Fitzgerald set a $2.00 price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report released on Tuesday. The brokerage currently has a hold rating on the biotechnology company’s stock.
Several other research firms also recently weighed in on ARWR. ValuEngine raised Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a report on Monday, October 2nd. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price objective on the stock in a report on Monday, November 27th. BidaskClub downgraded Arrowhead Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, December 2nd. William Blair raised Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. Finally, Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $3.17.
Arrowhead Pharmaceuticals (ARWR) traded down $0.25 during midday trading on Tuesday, hitting $3.15. The company had a trading volume of 1,702,100 shares, compared to its average volume of 984,368. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.84 and a current ratio of 3.63. Arrowhead Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $4.54.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.